Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
about
LipidII: Just Another Brick in the Wall?Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature.Synergistic binding of the leader and core peptides by the lantibiotic synthetase HalM2.Chemical synthesis and biological activity of analogues of the lantibiotic epilancin 15X.Non-proteinogenic amino acids in lacticin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation.Structural Characterization and Bioactivity Analysis of the Two-Component Lantibiotic Flv System from a Ruminant Bacterium.The Mechanism of Action of Lysobactin.Chemical synthesis of the lantibiotic lacticin 481 reveals the importance of lanthionine stereochemistry.A general method for fluorescent labeling of the N-termini of lanthipeptides and its application to visualize their cellular localization.Saturation mutagenesis of selected residues of the α-peptide of the lantibiotic lacticin 3147 yields a derivative with enhanced antimicrobial activityLipoprotein activators stimulate Escherichia coli penicillin-binding proteins by different mechanisms.Contribution of the Actinobacteria to the growing diversity of lantibiotics.Peptide antimicrobials: cell wall as a bacterial target.Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential.Cell Wall-active Bacteriocins and Their Applications Beyond Antibiotic Activity.New Found Hope for Antibiotic Discovery: Lipid II Inhibitors.Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.Targeting a cell wall biosynthesis hot spot.Towards Biocontained Cell Factories: An Evolutionarily Adapted Escherichia coli Strain Produces a New-to-nature Bioactive Lantibiotic Containing Thienopyrrole-Alanine.Envelope Structures of Gram-Positive Bacteria.
P2860
Q26775024-99B51F7F-014B-40C7-903E-ED6C2C992AC4Q34312732-28B29187-4C41-4165-87F7-0A5D40A21EF6Q35554358-90A626B7-04C8-4B9B-9531-BC9E67F71DFAQ35949915-F44AE3C6-EDCB-4EE9-B267-8525D4EA5E54Q36408239-D1196E84-F0B5-4CE0-A3B2-407BD656CC92Q36748438-3718D455-47C8-4839-BB2A-32F9E8A1F69FQ36756629-B3DC2301-7962-41A7-9B8B-6E391FBE6644Q37078724-CF961BC5-10FD-4CB8-9C7E-C47093410786Q37177787-0AE1C2B8-9142-4647-B8DA-A9BCD48CDE07Q37569003-9CFE27C2-365B-4F56-9C05-5C31280ADE9FQ37653414-A920F0C2-FEE1-4D27-AECB-255254B91A97Q38038546-33C454E0-BB33-4EB5-A464-D9FD2D21C611Q38072770-1BEFBF99-B489-48D1-9CF1-F17D00D96110Q38177305-03733804-CDB0-4A10-9656-E1E82904F55AQ38702083-8EB9CD77-AEE4-4AEC-B3E8-CC34884B77AAQ38889355-D595152F-7F68-445E-A861-0FE44A3A0570Q39109460-F42A31EE-7CEC-4872-ACC9-8EF4518F187AQ39413308-C6BB9C1F-2FFB-4EF0-BEA3-39948FA80411Q41107514-48936EEC-4D4A-45B9-9969-EB6F7B2BBDB3Q53163130-C6107682-378C-431E-9ABB-C003C7CC8FAB
P2860
Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
@ast
Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
@en
type
label
Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
@ast
Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
@en
prefLabel
Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
@ast
Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
@en
P2093
P2860
P356
P1476
Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry
@en
P2093
Daniel Kahne
Suzanne Walker
Tania J Lupoli
Trent J Oman
P2860
P304
17544-17547
P356
10.1021/JA206281K
P407
P577
2011-10-17T00:00:00Z